









Markets
/
Stocks
/
nasdaq-nxtc
/

NextCure Inc

NXTC

9.640USD

-2.340-19.53%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

1.88MMarket Cap

LossP/E TTM



NextCure Inc

9.640

-2.340-19.53%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of NextCure Inc

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

NextCure Inc's Score

Industry at a Glance

Industry Ranking

137 / 407

Overall Ranking

257 / 4616

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 3 analysts

Buy

Current Rating

17.500

Target Price

+46.08%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

NextCure Inc Highlights

StrengthsRisks

NextCure, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on advancing medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of actions including Antibody-Drug Conjugates (ADCs), antibodies, and proteins. The Company focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidates include NC410 and LNCB74. Its Clinical Oncology Programs are NC525 and NC318. Its Pre-Clinical Non-Oncology Programs are NC605 and NC181. NC410 is a LAIR-2 fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers. NCB74 is an ADC that is directed to B7-H4, a clinically validated cancer target.

Overvalued

The company’s latest PE is -0.05, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 873.34K shares, decreasing 41.16% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 41.74K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.86.

Financial Health

Currency: USD Updated: 2025-11-04

The company's current financial score is 6.27, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.27

Change



Financials

5.87

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.86

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

3.86

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

NextCure Inc's Company Valuation

Currency: USD Updated: 2025-11-04

The company’s current valuation score is 7.28, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -0.05, which is -95.80% below the recent high of -0.00 and -2187.39% above the recent low of -1.09.

Score

Industry at a Glance

Previous score

7.28

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 137/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-04

The company’s current earnings forecast score is 7.33, which is lower than the Biotechnology & Medical Research industry's average of 8.00. The average price target for NextCure Inc is 17.50, with a high of 20.00 and a low of 15.00.

Score

Industry at a Glance

Previous score

7.33

Change

Support & Resistance

No Data

Analyst Rating

Based on 3 analysts

Buy

Current Rating

17.500

Target Price

+46.08%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

NextCure Inc

NXTC

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-04

The company’s current price momentum score is 7.65, which is higher than the Biotechnology & Medical Research industry's average of 6.41. Sideways: Currently, the stock price is trading between the resistance level at 13.15 and the support level at 6.14, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.62

Change

-1.97

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.101

Buy

RSI(14)

52.936

Neutral

STOCH(KDJ)(9,3,3)

51.881

Sell

ATR(14)

1.891

Low Volatility

CCI(14)

-20.528

Neutral

Williams %R

54.644

Neutral

TRIX(12,20)

2.867

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

11.688

Sell

MA10

10.518

Sell

MA20

9.417

Buy

MA50

7.047

Buy

MA100

5.193

Buy

MA200

2.884

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-04

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.15. The latest institutional shareholding proportion is 32.63%, representing a quarter-over-quarter decrease of 33.41%. The largest institutional shareholder is The Vanguard, holding a total of 72.67K shares, representing 2.72% of shares outstanding, with 22.97% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Simcere Zaiming, Inc

338.64K

Sofinnova Investments, Inc

222.66K

Affinity Asset Advisors LLC

191.88K

Citi Investment Research (US)

85.46K

-27.75%

The Vanguard Group, Inc.

Star Investors

72.67K

-11.68%

Cable Car Capital LLC

63.18K

+13.14%

Renaissance Technologies LLC

Star Investors

41.74K

+4.37%

Acadian Asset Management LLC

40.70K

Richman (Michael S)

34.69K

+2.46%

Risk Assessment

Currency: USD Updated: 2025-11-04

The company’s current risk assessment score is 2.59, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 1.56. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.